Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares - CANF STOCK NEWS

Can-Fite BioPharma (NYSE American: CANF; TASE: CANF), a biotechnology firm focused on small molecule drugs for oncological and inflammatory diseases, invites investors to a webinar on June 6, 2024, at 4:15 p.m. ET.

Hosted by RedChip Companies, the event will feature CEO Motti Farbstein and Executive Chairperson/Chief Scientific Officer Pnina Fishman, PhD. They will discuss the company's current development pipeline and upcoming milestones.

Investors can register for the free webinar and pre-submit questions at the provided link.

Can-Fite BioPharma held a conference for 75 oncologists and coordinators to accelerate patient enrollment for the pivotal Phase 3 advanced liver cancer study. The study aims to evaluate Namodenoson as a 2nd or 3rd line treatment for CPB7 patients with HCC. The drug has Orphan Drug status and Fast Track Status with the FDA for HCC treatment. The market for HCC treatments is projected to reach $6.1 billion by 2027.

RedChip Companies will air interviews with Can-Fite BioPharma (NYSE American:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, discusses the company's advanced clinical stage drug development focusing on oncology and inflammatory diseases. Can-Fite has two drug candidates in advanced stages of development with registration plans agreed with the U.S. FDA and the EMA. Gareth Sheridan, Founder and CEO of Nutriband, talks about their AVERSA™ abuse-deterrent transdermal technology to address the global opioid crisis. Nutriband's lead product, AVERSA™ Fentanyl, is targeting peak annual sales of $80 million to $200 million.

Can-Fite BioPharma has received FDA clearance for its small molecule drug, Namodenoson, to treat MASH patients in a Phase IIb study. The drug targets the A3 adenosine receptor in liver cells, showing promise in reducing hepatic steatosis, inflammation, and fibrosis. The Phase IIb trial aims to evaluate Namodenoson's efficacy in 140 MASH patients, with enrollment now open in the US.

Can-Fite BioPharma (NYSE American: CANF) received a Notice of Allowance from the European Patent Office for its patent application related to the use of the CF602 drug candidate for the treatment of erectile dysfunction in patients such as diabetics. The patent has already been issued in other major markets. Can-Fite's CF602 showed promising results in a diabetic rat model, offering an alternative for non-responders to current ED drugs. The company sees this as a significant addition to their IP estate, positioning CF602 as a potential treatment for sexual dysfunction.

Can-Fite BioPharma announced the publication of an article in a scientific journal detailing a long-term complete response to namodenoson in a patient with advanced liver cancer. The patient has been treated for over 7 years, showing improved liver function and quality of life. Can-Fite's Phase III clinical study for namodenoson is ongoing, targeting patients with advanced liver disease. The drug has received Orphan Drug status and Fast Track Status for the treatment of hepatocellular carcinoma (HCC). The market for HCC treatments is expected to grow significantly by 2027.

Can-Fite BioPharma announces the publication of a scientific article by a key opinion leader highlighting Namodenoson as a potential treatment for advanced liver cancer and MASH. The article discusses the drug's mechanism of action and its positive effects in liver cancer and MASH, with ongoing Phase III and Phase IIb trials.

Can-Fite BioPharma submits IND application to FDA for Phase IIb study of Namodenoson in treating MASH, demonstrating positive effects in reducing hepatic steatosis, inflammation, and fibrosis.

Can-Fite BioPharma, (CANF) to present at The 14th Annual LD Micro Invitational in New York. CEO Motti Farbstein to lead the presentation on April 9th, 2024.